(BGM) Qilian International - Ratings and Ratios
Exchange: NASDAQ • Country: China • Currency: USD • Type: Common Stock •
BGM: Pharmaceuticals, Medicine, Licorice, Fertilizers, Animal Health Products
BGM Group Ltd, formerly known as Qilian International Holding Group Limited, is a China-based pharmaceutical and agrochemical company listed on the NASDAQ under the ticker symbol BGM. Since its incorporation in 2019, the company has specialized in manufacturing and distributing active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and related by-products. Its product portfolio includes licorice derivatives, such as Gan Di Xin, used as an antitussive and expectorant, and Qilian Shan Licorice Extract, which serves as a key ingredient for pharmaceutical companies producing traditional licorice tablets. The company also offers Qilian Shan licorice liquid extract, a primary component for manufacturing compound licorice oral solutions.
BGM Group Ltd provides veterinary and human healthcare solutions through its Qilian Shan oxytetracycline tablets and APIs, which are used to prevent and treat diseases in livestock and humans. Additionally, the company produces TCMD products, including Ahan antibacterial paste for treating chronic skin conditions and heparin sodium preparations for cardiovascular and cerebrovascular medications. Its non-pharmaceutical offerings include Zhu Xiaochang sausage casings for culinary applications and Xiongguan organic and organic-inorganic compound fertilizers, designed to enhance crop yields and soil health. The company operates from its headquarters in Chengdu, Sichuan Province, China, and maintains a strong focus on research, development, and distribution across its diversified product lines.
Based on the provided
Additional Sources for BGM Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BGM Stock Overview
Market Cap in USD | 47m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2024-08-12 |
BGM Stock Ratings
Growth 5y | -38.4% |
Fundamental | -24.4% |
Dividend | 1.0% |
Rel. Strength Industry | 202 |
Analysts | - |
Fair Price Momentum | 9.42 USD |
Fair Price DCF | - |
BGM Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | -100.00% |
Payout Consistency | 1.0% |
BGM Growth Ratios
Growth Correlation 3m | 50.5% |
Growth Correlation 12m | 94.9% |
Growth Correlation 5y | -66.2% |
CAGR 5y | -31.85% |
CAGR/Max DD 5y | -0.33 |
Sharpe Ratio 12m | -0.30 |
Alpha | 196.46 |
Beta | 0.22 |
Volatility | 79.98% |
Current Volume | 6.1k |
Average Volume 20d | 4.9k |
As of March 14, 2025, the stock is trading at USD 9.80 with a total of 6,085 shares traded.
Over the past week, the price has changed by -7.42%, over one month by -5.41%, over three months by +13.95% and over the past year by +201.54%.
Neither. Based on ValueRay Fundamental Analyses, Qilian International is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -24.36 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BGM as of March 2025 is 9.42. This means that BGM is currently overvalued and has a potential downside of -3.88%.
Qilian International has no consensus analysts rating.
According to ValueRays Forecast Model, BGM Qilian International will be worth about 10.2 in March 2026. The stock is currently trading at 9.80. This means that the stock has a potential upside of +4.08%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 10.2 | 4.1% |